Key Takeaways
- • Monogram Capital closed a single-asset continuation fund for Mountaintop Beverage, moving the contract manufacturer out of Monogram Capital Partners II with Apollo S3 (Apollo Global Management's sponsor and secondary platform) as lead investor, alongside Partners Capital, TIFF, and H7 Capital.
- • Mountaintop specializes in low-acid aseptic processing and extended-shelf-life (ESL) manufacturing for shelf-stable and refrigerated functional beverages, serving fast-growing protein, coffee, dairy, plant-based milk, and tea brands that lack in-house manufacturing capacity.
- • The continuation fund returns majority capital to Monogram II investors while Monogram management and Mountaintop's leadership roll substantial stakes into the new vehicle, committing fresh capital for a 250,000-square-foot capacity expansion and future acquisitions.
- • The U.S. domestic contract bottling and filling market is valued at $4.1 billion in 2025 and forecast to reach $6 billion by 2030 (7.7% CAGR), with aseptic filling as the fastest-expanding segment driven by shelf-stable format demand and functional ready-to-drink beverages (26% unit volume growth in 2025).
- • Mountaintop, led by CEO Jeff Sokal and headquartered in Morgantown, West Virginia, operates as a capacity-constrained, technically specialized supply chain partner positioned to become the largest low-acid PET bottle contract manufacturer in North America.
Summary
Monogram Capital has successfully closed a continuation fund vehicle for Mountaintop Beverage, a specialized contract manufacturer of shelf-stable and refrigerated beverages. The transaction, led by Apollo S3—Apollo Global Management's platform for sponsor and secondary transactions—represents a recapitalization and extension of Monogram's August 2021 initial investment in the company. Additional investors in the continuation fund include Partners Capital, TIFF, H7 Capital, and other institutional investors. The structure returns the majority of capital from Monogram Capital Partners II to that fund's limited partners while allowing Monogram's management team and Mountaintop's leadership to maintain substantial equity stakes in the new vehicle and commit fresh capital for growth initiatives.
Mountaintop's core competitive advantage lies in its proprietary expertise in low-acid aseptic processing—a technically demanding sterilization method that separates beverage and packaging sterilization before combining them in a sterile environment, eliminating the need for preservatives in shelf-stable products. This capability powers shelf-stable protein shakes, ready-to-drink coffees, and dairy and plant-based milk products. The company also operates extended-shelf-life (ESL) production lines for chilled products requiring extended refrigerated longevity. Headquartered approximately 70 miles south of Pittsburgh in Morgantown, West Virginia, Mountaintop serves fast-growing functional and "better-for-you" beverage brands across protein, coffee, dairy, plant-based, and tea categories—many of which lack the capital and technical expertise to operate their own manufacturing facilities.
The contract beverage manufacturing market represents a high-growth segment of the U.S. supply chain. According to Mordor Intelligence, the domestic contract bottling and filling market was valued at approximately $4.1 billion in 2025 and is projected to reach roughly $6 billion by 2030, representing a compound annual growth rate of 7.7 percent. Aseptic filling is the fastest-expanding subsegment, driven by accelerating brand demand for shelf-stable formats. Functional ready-to-drink beverages experienced particular momentum, with unit volumes jumping approximately 26 percent in 2025. The economics of this market favor specialized operators: aseptic and high-pressure processing lines require substantial capital investment and technical expertise, creating a structural advantage for co-manufacturers capable of spreading these assets across multiple customers while operating in segments where capacity remains scarce relative to demand.
The continuation fund commits fresh capital to support a 250,000-square-foot capacity expansion and potential acquisitions, positioning Mountaintop to scale its low-acid aseptic capabilities and expand into PET plastic bottle filling—a format experiencing accelerating demand for protein and functional beverages. CEO Jeff Sokal noted that the transaction preserves operational continuity with the existing management team and board while adding Apollo S3 as a capital partner with secondary market expertise. Jared Stein, co-founder and partner at Monogram Capital Partners, characterized Mountaintop as embodying Monogram's investment thesis around technically complex, capacity-constrained supply chain businesses serving fast-growing consumer brands. Veena Isaac, partner and co-head of Apollo S3, emphasized that the company's category-leading position in a highly specialized segment with genuine capacity scarcity makes it an attractive platform for patient, institutional capital deployment.
Mountaintop's core competitive advantage lies in its proprietary expertise in low-acid aseptic processing—a technically demanding sterilization method that separates beverage and packaging sterilization before combining them in a sterile environment, eliminating the need for preservatives in shelf-stable products. This capability powers shelf-stable protein shakes, ready-to-drink coffees, and dairy and plant-based milk products. The company also operates extended-shelf-life (ESL) production lines for chilled products requiring extended refrigerated longevity. Headquartered approximately 70 miles south of Pittsburgh in Morgantown, West Virginia, Mountaintop serves fast-growing functional and "better-for-you" beverage brands across protein, coffee, dairy, plant-based, and tea categories—many of which lack the capital and technical expertise to operate their own manufacturing facilities.
The contract beverage manufacturing market represents a high-growth segment of the U.S. supply chain. According to Mordor Intelligence, the domestic contract bottling and filling market was valued at approximately $4.1 billion in 2025 and is projected to reach roughly $6 billion by 2030, representing a compound annual growth rate of 7.7 percent. Aseptic filling is the fastest-expanding subsegment, driven by accelerating brand demand for shelf-stable formats. Functional ready-to-drink beverages experienced particular momentum, with unit volumes jumping approximately 26 percent in 2025. The economics of this market favor specialized operators: aseptic and high-pressure processing lines require substantial capital investment and technical expertise, creating a structural advantage for co-manufacturers capable of spreading these assets across multiple customers while operating in segments where capacity remains scarce relative to demand.
The continuation fund commits fresh capital to support a 250,000-square-foot capacity expansion and potential acquisitions, positioning Mountaintop to scale its low-acid aseptic capabilities and expand into PET plastic bottle filling—a format experiencing accelerating demand for protein and functional beverages. CEO Jeff Sokal noted that the transaction preserves operational continuity with the existing management team and board while adding Apollo S3 as a capital partner with secondary market expertise. Jared Stein, co-founder and partner at Monogram Capital Partners, characterized Mountaintop as embodying Monogram's investment thesis around technically complex, capacity-constrained supply chain businesses serving fast-growing consumer brands. Veena Isaac, partner and co-head of Apollo S3, emphasized that the company's category-leading position in a highly specialized segment with genuine capacity scarcity makes it an attractive platform for patient, institutional capital deployment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.